vs
Side-by-side financial comparison of CIVITAS RESOURCES, INC. (CIVI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
CIVITAS RESOURCES, INC. is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -8.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 1.8%).
Civitas Resources, Inc. is a U.S.-based sustainable energy enterprise focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It primarily operates across the Denver-Julesburg Basin in Colorado, prioritizing low-emission, responsible energy production to meet diverse North American energy demand.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
CIVI vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $622.0M |
| Net Profit | — | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 20.0% | 62.4% |
| Net Margin | — | 34.4% |
| Revenue YoY | -8.2% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | $1.99 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0M | ||
| Q3 25 | $1.2B | $609.3M | ||
| Q2 25 | $1.1B | $578.7M | ||
| Q1 25 | $1.2B | $568.2M | ||
| Q4 24 | $1.3B | $593.6M | ||
| Q3 24 | $1.3B | $564.7M | ||
| Q2 24 | $1.3B | $537.3M | ||
| Q1 24 | $1.3B | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | — | $544.0M | ||
| Q2 24 | — | $102.0M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | 20.0% | 70.1% | ||
| Q2 25 | 15.3% | 36.3% | ||
| Q1 25 | 20.7% | 94.0% | ||
| Q4 24 | 15.4% | 60.9% | ||
| Q3 24 | 30.6% | — | ||
| Q2 24 | 21.6% | 50.2% | ||
| Q1 24 | 15.9% | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | — | 96.3% | ||
| Q2 24 | — | 19.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $1.99 | $0.67 | ||
| Q2 25 | $1.34 | $0.07 | ||
| Q1 25 | $1.99 | $0.55 | ||
| Q4 24 | $1.56 | $0.46 | ||
| Q3 24 | $3.01 | $1.21 | ||
| Q2 24 | $2.15 | $0.23 | ||
| Q1 24 | $1.74 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $618.7M |
| Total DebtLower is stronger | $5.1B | $9.0B |
| Stockholders' EquityBook value | $6.7B | $9.7B |
| Total Assets | $15.1B | $19.6B |
| Debt / EquityLower = less leverage | 0.77× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | $56.0M | $938.9M | ||
| Q2 25 | $69.0M | $631.9M | ||
| Q1 25 | $20.0M | $1.1B | ||
| Q4 24 | $76.0M | $929.0M | ||
| Q3 24 | $47.1M | $950.1M | ||
| Q2 24 | $91.9M | $1.8B | ||
| Q1 24 | $52.1M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $5.1B | $8.9B | ||
| Q2 25 | $5.4B | $8.0B | ||
| Q1 25 | $5.1B | $7.6B | ||
| Q4 24 | $4.5B | $7.6B | ||
| Q3 24 | $4.8B | $7.6B | ||
| Q2 24 | $4.9B | $7.6B | ||
| Q1 24 | $4.4B | $6.1B |
| Q4 25 | — | $9.7B | ||
| Q3 25 | $6.7B | $9.6B | ||
| Q2 25 | $6.8B | $9.5B | ||
| Q1 25 | $6.7B | $9.8B | ||
| Q4 24 | $6.6B | $10.3B | ||
| Q3 24 | $6.7B | $10.3B | ||
| Q2 24 | $6.6B | $9.8B | ||
| Q1 24 | $6.6B | $9.9B |
| Q4 25 | — | $19.6B | ||
| Q3 25 | $15.1B | $19.3B | ||
| Q2 25 | $15.4B | $18.3B | ||
| Q1 25 | $15.3B | $17.6B | ||
| Q4 24 | $14.9B | $18.2B | ||
| Q3 24 | $15.0B | $18.0B | ||
| Q2 24 | $15.0B | $17.7B | ||
| Q1 24 | $15.1B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.77× | 0.93× | ||
| Q2 25 | 0.79× | 0.84× | ||
| Q1 25 | 0.76× | 0.78× | ||
| Q4 24 | 0.68× | 0.74× | ||
| Q3 24 | 0.73× | 0.74× | ||
| Q2 24 | 0.74× | 0.78× | ||
| Q1 24 | 0.67× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $860.0M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $860.0M | $702.6M | ||
| Q2 25 | $298.0M | $364.0M | ||
| Q1 25 | $719.0M | $596.1M | ||
| Q4 24 | $858.2M | $742.5M | ||
| Q3 24 | $835.0M | $703.6M | ||
| Q2 24 | $359.0M | $658.2M | ||
| Q1 24 | $813.0M | $664.6M |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVI
| Crude Oil Natural Gas And Natural Gas Liquids | $1.2B | 99% |
| Oil And Gas Operation And Maintenance | $8.0M | 1% |
| Natural Gas Reserves | $2.0M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
